Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says

Don't Miss Out —
Follow us on:

March 7 (Bloomberg) -- Novartis AG’s development of a version of the best-selling drug Rituxan is proceeding as planned, Jeff George, who heads the company’s Sandoz generics unit, said in an interview today.

“Our program is on track,” George said in Tokyo today. “But we’ve never given a time line as to when we are coming to market with the product.”

Companies including Boehringer Ingelheim GmbH are racing to bring a biosimilar version of the drug, also known as rituximab, to the market. The original compound, sold by Roche Holding AG and Biogen Idec Inc., had about $7 billion in sales last year. Roche’s Chief Executive Officer Severin Schwan said in January that the introduction of Sandoz’s product may be delayed until 2016, Bloomberg Industries analysts wrote in a note.

“What I can say is that a number of competitors have faced issues with their clinical trial programs,” George said.

Sandoz is running trials in the two most important indications of the drug, rheumatoid arthritis and non-Hodgkin’s lymphoma. Rituxan is also sold as MabThera.

To contact the reporters on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net; Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net; Jason Gale at j.gale@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.